Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.

ग्रंथसूची विवरण
मुख्य लेखकों:	Holman, R, Sourij, H, Califf, R
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	Lancet 2014

समान संसाधन

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
द्वारा: Holman, R, और अन्य
प्रकाशित: (2014)

Untitled reply
द्वारा: Holman, R, और अन्य
प्रकाशित: (2014)

Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply
द्वारा: Holman, RR, और अन्य
प्रकाशित: (2015)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
द्वारा: Califf, R, और अन्य
प्रकाशित: (2003)

Microvascular outcomes in type 2 diabetes - Authors' reply
द्वारा: Zoungas, S, और अन्य
प्रकाशित: (2017)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
द्वारा: Califf, R, और अन्य
प्रकाशित: (2008)

Follow-up of Intensive Glucose Control in Type 2 Diabetes Reply
द्वारा: Holman, R, और अन्य
प्रकाशित: (2009)

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
द्वारा: Bethel, M, और अन्य
प्रकाशित: (2009)

Blood pressure lowering and cardiovascular risk - Authors' reply.
द्वारा: Sundström, J, और अन्य
प्रकाशित: (2014)

The authors reply
द्वारा: Holman, R, और अन्य
प्रकाशित: (2010)

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
द्वारा: Green, J, और अन्य
प्रकाशित: (2013)

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - authors' reply
द्वारा: Nazarzadeh, M, और अन्य
प्रकाशित: (2022)

Blood pressure lowering for cardiovascular disease - Authors' reply
द्वारा: Ettehad, D, और अन्य
प्रकाशित: (2016)

The authors reply
द्वारा: Holman, R, और अन्य
प्रकाशित: (2009)

The authors reply
द्वारा: Holman, R, और अन्य
प्रकाशित: (2008)

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
द्वारा: Green, J, और अन्य
प्रकाशित: (2013)

The authors reply
द्वारा: Holman, R, और अन्य
प्रकाशित: (2010)

Calculation of coronary risk in Type II diabetes: another cause for concern: authors' reply
द्वारा: Holman, R, और अन्य
प्रकाशित: (2002)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
द्वारा: M. Angelyn Bethel, और अन्य
प्रकाशित: (2023-03-01)

METFORMIN IN THE MANAGEMENT OF TYPE-2 DIABETES - REPLY
द्वारा: Holman, R, और अन्य
प्रकाशित: (1989)

Improving glucose control and cardiovascular risk in general practice Type 2 diabetes.
द्वारा: Potts, N, और अन्य
प्रकाशित: (2003)

Insulin Regimens in Type 2 Diabetes REPLY
द्वारा: Holman, R, और अन्य
प्रकाशित: (2010)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
द्वारा: Krum, H, और अन्य
प्रकाशित: (2010)

Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.
द्वारा: Colagiuri, S, और अन्य
प्रकाशित: (2002)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
द्वारा: Mcmurray, J, और अन्य
प्रकाशित: (2011)

Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
द्वारा: Holman, R, और अन्य
प्रकाशित: (2015)

Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective
द्वारा: Felix Aberer, और अन्य
प्रकाशित: (2022-05-01)

Diabetic microvascular triopathy, smoking, and risk of cardiovascular events - Author's reply
द्वारा: Brownrigg, J, और अन्य
प्रकाशित: (2016)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
द्वारा: Preiss, D, और अन्य
प्रकाशित: (2012)

Statins and diabetes - Authors' reply
द्वारा: Kearney, P, और अन्य
प्रकाशित: (2008)

EVALUATION OF A NEW BLOOD-GLUCOSE METER - REPLY
द्वारा: Matthews, D, और अन्य
प्रकाशित: (1987)

Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
द्वारा: Bethel, M, और अन्य
प्रकाशित: (2007)

Addition of insulin to oral therapy in type 2 diabetes - Reply
द्वारा: Holman, R, और अन्य
प्रकाशित: (2008)

The BALANCE trial - Authors' reply
द्वारा: Geddes, J, और अन्य
प्रकाशित: (2010)

Women develop diabetes at higher BMIs than men.
द्वारा: Sourij, H, और अन्य
प्रकाशित: (2012)

Women develop diabetes at higher BMIs than men
द्वारा: Sourij, H, और अन्य
प्रकाशित: (2012)

From trial to practice Authors' reply
द्वारा: Glasziou, P, और अन्य
प्रकाशित: (2010)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
द्वारा: Preiss, D, और अन्य
प्रकाशित: (2013)

Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T)
द्वारा: Levy, J, और अन्य
प्रकाशित: (2017)

The UK Prospective Diabetes Study - Reply
द्वारा: Turner, R, और अन्य
प्रकाशित: (1998)